Trial · NCT00527124
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 6-month Progression-free Survival (PFS) Proportion | Arm I | 60 | 95% Confidence Interval 42 to 75 | percentage of patients | |
| 6-month Progression-free Survival (PFS) Proportion | Arm II | 54 | 95% Confidence Interval 36 to 71 | percentage of patients | |
| Prostate-specific Antigen (PSA) Response in Accordance With the Prostate Specific Antigen Working Group | Arm I | CR | .35 | 95% Confidence Interval .19 to .54 | proportion of evaluable patients |
| Prostate-specific Antigen (PSA) Response in Accordance With the Prostate Specific Antigen Working Group | Arm II | CR | .12 | 95% Confidence Interval .04 to .29 | proportion of evaluable patients |
| Prostate-specific Antigen (PSA) Response in Accordance With the Prostate Specific Antigen Working Group | Arm I | PR | .27 | 95% Confidence Interval .14 to .46 | proportion of evaluable patients |
| Prostate-specific Antigen (PSA) Response in Accordance With the Prostate Specific Antigen Working Group | Arm II | PR | .54 | 95% Confidence Interval .35 to .71 | proportion of evaluable patients |
| Prostate-specific Antigen (PSA) Response in Accordance With the Prostate Specific Antigen Working Group | Arm I | SD | .35 | 95% Confidence Interval .19 to .54 | proportion of evaluable patients |
| Prostate-specific Antigen (PSA) Response in Accordance With the Prostate Specific Antigen Working Group | Arm II | SD | .31 | 95% Confidence Interval .17 to .50 | proportion of evaluable patients |
| Prostate-specific Antigen (PSA) Response in Accordance With the Prostate Specific Antigen Working Group | Arm I | PD | .04 | 95% Confidence Interval .01 to .19 | proportion of evaluable patients |
| Prostate-specific Antigen (PSA) Response in Accordance With the Prostate Specific Antigen Working Group | Arm II | PD | .04 | 95% Confidence Interval .01 to .19 | proportion of evaluable patients |
| Overall Response Rate Evaluated by the RECIST Criteria | Arm I | SD | .92 | 95% Confidence Interval .75 to .98 | proportion of evaluable patients |
| Overall Response Rate Evaluated by the RECIST Criteria | Arm II | SD | .92 | 95% Confidence Interval .76 to .98 | proportion of evaluable patients |
| Overall Response Rate Evaluated by the RECIST Criteria | Arm I | PD | .08 | 95% Confidence Interval .02 to .25 | proportion of evaluable patients |
| Overall Response Rate Evaluated by the RECIST Criteria | Arm II | PD | .08 | 95% Confidence Interval .02 to .24 | proportion of evaluable patients |
| Time to Progression | Arm I | 8.0 | 95% Confidence Interval 4.2 to 11.9 | months | |
| Time to Progression | Arm II | 6.4 | 95% Confidence Interval 4.8 to 10.2 | months | |
| Overall Survival | Arm I | 71 | 95% Confidence Interval 51 to 84 | percentage of patients | |
| Overall Survival | Arm II | 76 | 95% Confidence Interval 55 to 88 | percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00527124/results